Stock listing
OTC:MDBIF TrivarX Limited Stock
US listing (OTC) of TrivarX Limited · home listing ASX:TRI
Follow TrivarX Limited into a list and get an email when it puts out news.
Share price · OTC:MDBIF
$0.0029 USD 0.0000 (0.0%)
Close on Nov 6, 2026
- Day range
- $0.0029 – $0.0029 USDNov 6, 2026
- 52-week range
- $0.0029 – $0.0278 USDLowest and highest trades, Nov 7, 2025 – Nov 6, 2026
- Traded on an average day
- $29 USDMedian day 0 shares · 50 days with no trades · last 3 months, Aug 6, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| ASX:TRI · Home | $0.0080 AUD | 0.0000 (0.0%) | 37,500 | $0.0080 | $0.0080 | $0.0080 | $0.0080 | Close on Nov 20, 2026 |
| OTC:MDBIF | $0.0029 USD | 0.0000 (0.0%) | — | $0.0029 | $0.0029 | $0.0029 | $0.0029 | Close on Nov 6, 2026 |
Daily closes
Last 3 months, Aug 6, 2026 – Nov 6, 2026 · OTC:MDBIF · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.0029 | 0.0000 | 0.0% | $0.0029 | $0.0029 | $0.0029 | 0 | |
| $0.0029 | 0.0000 | 0.0% | $0.0029 | $0.0029 | $0.0029 | 0 | |
| $0.0029 | 0.0000 | 0.0% | $0.0029 | $0.0029 | $0.0029 | 0 | |
| $0.0029 | 0.0000 | 0.0% | $0.0029 | $0.0029 | $0.0029 | 0 | |
| $0.0029 | 0.0000 | 0.0% | $0.0029 | $0.0029 | $0.0029 | 0 | |
| $0.0029 | 0.0000 | 0.0% | $0.0029 | $0.0029 | $0.0029 | 0 | |
| $0.0029 | -0.0042 | -59.2% | $0.0043 | $0.0043 | $0.0029 | 67,500 | |
| $0.0071 | 0.0000 | 0.0% | $0.0071 | $0.0071 | $0.0071 | 0 | |
| $0.0071 | 0.0000 | 0.0% | $0.0071 | $0.0071 | $0.0071 | 0 | |
| $0.0071 | 0.0000 | 0.0% | $0.0071 | $0.0071 | $0.0071 | 0 | |
| $0.0071 | 0.0000 | 0.0% | $0.0071 | $0.0071 | $0.0071 | 0 | |
| $0.0071 | 0.0000 | 0.0% | $0.0071 | $0.0071 | $0.0071 | 0 | |
| $0.0071 | 0.0000 | 0.0% | $0.0071 | $0.0071 | $0.0071 | 0 | |
| $0.0071 | 0.0000 | 0.0% | $0.0071 | $0.0071 | $0.0071 | 0 | |
| $0.0071 | 0.0000 | 0.0% | $0.0071 | $0.0071 | $0.0071 | 0 | |
| $0.0071 | 0.0000 | 0.0% | $0.0071 | $0.0071 | $0.0071 | 0 | |
| $0.0071 | -0.0010 | -12.3% | $0.0071 | $0.0071 | $0.0071 | 21,840 | |
| $0.0081 | 0.0000 | 0.0% | $0.0081 | $0.0081 | $0.0081 | 0 | |
| $0.0081 | 0.0000 | 0.0% | $0.0081 | $0.0081 | $0.0081 | 0 | |
| $0.0081 | 0.0000 | 0.0% | $0.0081 | $0.0081 | $0.0081 | 0 | |
| $0.0081 | 0.0000 | 0.0% | $0.0081 | $0.0081 | $0.0081 | 0 | |
| $0.0081 | 0.0000 | 0.0% | $0.0081 | $0.0081 | $0.0081 | 0 | |
| $0.0081 | 0.0000 | 0.0% | $0.0081 | $0.0081 | $0.0081 | 0 | |
| $0.0081 | 0.0000 | 0.0% | $0.0081 | $0.0081 | $0.0081 | 0 | |
| $0.0081 | 0.0000 | 0.0% | $0.0081 | $0.0081 | $0.0081 | 0 | |
| $0.0081 | 0.0000 | 0.0% | $0.0081 | $0.0081 | $0.0081 | 0 | |
| $0.0081 | -0.0014 | -14.7% | $0.0081 | $0.0081 | $0.0081 | 60,975 | |
| $0.0095 | 0.0000 | 0.0% | $0.0095 | $0.0095 | $0.0095 | 0 | |
| $0.0095 | 0.0000 | 0.0% | $0.0095 | $0.0095 | $0.0095 | 0 | |
| $0.0095 | 0.0000 | 0.0% | $0.0095 | $0.0095 | $0.0095 | 0 | |
| $0.0095 | 0.0000 | 0.0% | $0.0095 | $0.0095 | $0.0095 | 0 | |
| $0.0095 | 0.0000 | 0.0% | $0.0095 | $0.0095 | $0.0095 | 0 | |
| $0.0095 | +0.0046 | +93.9% | $0.0069 | $0.0095 | $0.0069 | 36,036 | |
| $0.0049 | -0.0051 | -51.0% | $0.0049 | $0.0049 | $0.0049 | 10,000 | |
| $0.0100 | 0.0000 | 0.0% | $0.0100 | $0.0100 | $0.0100 | 0 | |
| $0.0100 | 0.0000 | 0.0% | $0.0100 | $0.0100 | $0.0100 | 0 | |
| $0.0100 | 0.0000 | 0.0% | $0.0100 | $0.0100 | $0.0100 | 0 | |
| $0.0100 | 0.0000 | 0.0% | $0.0100 | $0.0100 | $0.0100 | 0 | |
| $0.0100 | -0.0169 | -62.8% | $0.0100 | $0.0100 | $0.0100 | 20,000 | |
| $0.0269 | 0.0000 | 0.0% | $0.0269 | $0.0269 | $0.0269 | 0 | |
| $0.0269 | 0.0000 | 0.0% | $0.0269 | $0.0269 | $0.0269 | 0 | |
| $0.0269 | 0.0000 | 0.0% | $0.0269 | $0.0269 | $0.0269 | 0 | |
| $0.0269 | 0.0000 | 0.0% | $0.0269 | $0.0269 | $0.0269 | 0 | |
| $0.0269 | 0.0000 | 0.0% | $0.0269 | $0.0269 | $0.0269 | 0 | |
| $0.0269 | 0.0000 | 0.0% | $0.0175 | $0.0269 | $0.0175 | 4,267 | |
| $0.0269 | 0.0000 | 0.0% | $0.0269 | $0.0269 | $0.0269 | 0 | |
| $0.0269 | 0.0000 | 0.0% | $0.0269 | $0.0269 | $0.0269 | 0 | |
| $0.0269 | 0.0000 | 0.0% | $0.0269 | $0.0269 | $0.0269 | 0 | |
| $0.0269 | 0.0000 | 0.0% | $0.0269 | $0.0269 | $0.0269 | 0 | |
| $0.0269 | 0.0000 | 0.0% | $0.0269 | $0.0269 | $0.0269 | 0 | |
| $0.0269 | 0.0000 | 0.0% | $0.0269 | $0.0269 | $0.0269 | 0 | |
| $0.0269 | 0.0000 | 0.0% | $0.0269 | $0.0269 | $0.0269 | 0 | |
| $0.0269 | 0.0000 | 0.0% | $0.0269 | $0.0269 | $0.0269 | 0 | |
| $0.0269 | 0.0000 | 0.0% | $0.0269 | $0.0269 | $0.0269 | 0 | |
| $0.0269 | -0.0009 | -3.2% | $0.0269 | $0.0269 | $0.0269 | 5,000 | |
| $0.0278 | 0.0000 | 0.0% | $0.0278 | $0.0278 | $0.0278 | 0 | |
| $0.0278 | 0.0000 | 0.0% | $0.0278 | $0.0278 | $0.0278 | 0 | |
| $0.0278 | 0.0000 | 0.0% | $0.0278 | $0.0278 | $0.0278 | 0 |
Splits
1 split · OTC:MDBIF · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-20 | Consolidation |
- Ticker
- OTC:MDBIF
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news release · Nov 10, 2026
TrivarX Appoints Emeritus Research for Phase 1 Study
Latest deck · Jun 25, 2026
JP Equity Partners 'Boom of the Biotech II' Investor Briefing (June 2026)
Conference · 17 slides
Latest news
September 2026 Quarterly Activities Report and Appendix 4C
Oct 29, 2026
Closed $0.0029 (0.0%) on Oct 30, 2026
Letter to Shareholders & Notice of AGM & Proxy Form
Oct 26, 2026
Closed $0.0071 (0.0%) on Oct 27, 2026
Syntro Health Appointed to Support Stabl-Im Clinical Program
Oct 21, 2026
Closed $0.0071 (0.0%) on Oct 22, 2026
Change of Director's Interest Notice - David Trimboli
Oct 14, 2026
Closed $0.0081 (0.0%) on Oct 14, 2026
Change of Director's Interest Notice - Chris Ntoumenopoulos
Oct 14, 2026
Closed $0.0081 (0.0%) on Oct 14, 2026
Notification of cessation of securities - TRI
Oct 14, 2026
Closed $0.0081 (0.0%) on Oct 14, 2026
Appendix 4G
Sep 29, 2026
Closed $0.0095 (0.0%) on Sep 29, 2026
Corporate Governance Statement
Sep 29, 2026
Closed $0.0095 (0.0%) on Sep 29, 2026
2026 Annual Report
Sep 29, 2026
Closed $0.0095 (0.0%) on Sep 29, 2026
TrivarX Limited on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 23 in the last 12 months · 194 in all · newest Nov 10, 2026 · oldest 2010
- Decks
- 5 decks · latest Jun 25, 2026
Where TrivarX Limited is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| ASX:TRI · Home listing | ASX | Australia | AUD |
| OTC:MDBIF · This page | OTC | United States | USD |
Valuation
Price/book 0.6× against a median of 2.1×: the lowest of 9 Biotechnology companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $6.91M AUD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.6×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| TrivarX Limited · ASX:TRI | US$6.11M | US$4.58M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | n/a |
| FibroBiologics, Inc. · NASDAQ:FBLG | US$6.34M | US$5.17M | n/a | n/a | n/a | 3.5× | n/a | 0.0× | 0.34 |
| GT Biopharma, Inc. · NASDAQ:GTBP | US$6.33M | −US$3.60M | n/a | n/a | n/a | 0.8× | n/a | 0.0× | 1.57 |
| Kyntra Bio, Inc. · NASDAQ:KYNB | US$6.32M | −US$33.97M | n/a | −6.4× | n/a | n/a | −326.0% | n/a | 1.58 |
| Acurx Pharmaceuticals, Inc. · NASDAQ:ACXP | US$6.30M | −US$3.35M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.31 |
| Enveric Biosciences, Inc. · NASDAQ:ENVB | US$6.04M | US$429,455 | n/a | n/a | n/a | 1.1× | n/a | 0.0× | 0.76 |
| Medicofarma Biotech Spolka Akcyjna · NEWCONNECT:MDB | US$6.03M | US$6.03M | n/a | 314× | n/a | 5.4× | n/a | 0.0× | n/a |
| Addex Therapeutics Ltd · SIX:ADXN | US$5.96M | US$5.13M | n/a | 68.2× | n/a | 2.6× | n/a | 0.0× | n/a |
| Argenica Therapeutics Ltd · ASX:AGN | US$5.95M | US$1.74M | n/a | n/a | n/a | 1.5× | n/a | 0.0× | n/a |
| Marvel Biosciences Corp · TSXV:MRVL | US$5.91M | US$6.04M | n/a | n/a | n/a | n/a | n/a | n/a | 0.91 |
| Exicure, Inc. · NASDAQ:XCUR | US$5.89M | US$4.67M | n/a | n/a | n/a | 3.1× | n/a | 0.0× | 0.49 |
| Median of the others | US$6.04M | US$3.20M | 68.2× | 2.1× | −326.0% | 0.0× | 0.91 |
Team and board
Officers
| Officer | Role |
|---|---|
| Danielle Meyrick | Chief Executive Officer |
| Kai Sun | Chief Operating Officer |
| Tony Keating | Executive Director |
Board
| Director | Role |
|---|---|
| David Trimboli | Non-executive Chairman |
| Chris Ntoumenopoulos | Non-executive Director |
| Tony Keating | Executive Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q4 2025 | Sep 29, 2025 | 0.0% |
| Q2 2025 | Feb 28, 2025 | 0.0% |
| Q2 2023 | Feb 24, 2023 · After close | 0.0% |
| Q4 2022 | Sep 30, 2022 | 0.0% |
| Q2 2022 | Feb 25, 2022 | −25.0% |
| Q4 2021 | Aug 31, 2021 | +7.1% |
| Q2 2021 | Feb 24, 2021 | −9.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| JP Equity Partners 'Boom of the Biotech II' Investor Briefing (June 2026) | Conference | 17 slides | Jun 25, 2026 |
| TechKnow Invest Roadshow July 2024 | Conference | 19 slides | Jul 30, 2024 |
| Investor Presentation (May 2024) | Investor deck | 16 slides | May 22, 2024 |
| Investor Presentation (November 2023) | Investor deck | 18 slides | Nov 16, 2023 |
| Shareholder Meeting (November 2020) | Shareholder meeting | 16 slides | Nov 12, 2020 |
Financials
Annual, in AUD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.13M | 893.3K | 22.1K | 40.0K | 101.7K | 133.5K | 364.6K | 204.9K | 23.1K | |
| Cost of revenue | 6.47M | 52.5K | 93.1K | 158 | 1.07K | 170.7K | 204.7K | 226.1K | 75.7K | 0 |
| Gross profit | -6.47M | -52.5K | -93.1K | 21.9K | 39.0K | -69.0K | -71.2K | 138.5K | 129.2K | 23.1K |
| Research and development | 10.3K | 26.4K | 14.3K | 307.1K | 802.9K | 430.8K | 360.0K | 394.9K | 3.26M | 4.32M |
| Selling, general and administrative | 1.30M | 974.3K | 1.07M | 701.3K | 1.05M | 1.19M | 1.87M | 4.54M | 9.49M | 2.90M |
| Operating income | -8.42M | -2.04M | -2.31M | -2.68M | -3.64M | -2.63M | -3.84M | -6.57M | -18.7M | -12.7M |
| Depreciation and amortization | 6.47M | 52.5K | 93.1K | 97.5K | 448.9K | 198.5K | 148.9K | 148.9K | 1.33M | 1.73M |
| EBITDA | -1.95M | -1.99M | -2.22M | -2.58M | -3.19M | -2.44M | -3.69M | -6.42M | -17.4M | -10.9M |
| Interest expense | 12.5K | 33.6K | 13.4K | 13.3K | 5.32K | 6.29K | 36.7K | 13.9K | 8.14K | 0 |
| Income before tax | -8.76M | -1.97M | -1.24M | -3.12M | -12.7M | -1.49M | -3.87M | -6.59M | -16.3M | -9.79M |
| Income tax | -1.03M | 955.0K | 8.69K | 1.17M | 828.5K | -148.9K | 0 | 0 | ||
| Net income | -8.76M | -943.2K | -1.24M | -3.12M | -12.7M | -1.49M | -4.70M | -6.59M | -16.3M | -9.79M |
| Earnings per share, basic | -0.96 | -0.00 | -0.00 | -0.02 | -0.12 | -0.02 | -0.01 | -0.03 | -0.08 | -0.08 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 2.44M | 1.25M | 848.1K | 214.1K | 1.03M | 2.31M | 812.5K | 1.33M | 6.12M | 5.01M |
| Short-term investments | 0 | |||||||||
| Receivables | 0 | 32.2K | 32.5K | 14.9K | 1.67M | 220.3K | ||||
| Current assets | 2.49M | 1.30M | 915.2K | 304.5K | 1.20M | 2.66M | 861.7K | 1.53M | 7.89M | 7.37M |
| Property, plant and equipment | 164.3K | 15.4K | 107.5K | 65.4K | 23.1K | 71.4K | ||||
| Goodwill | 0 | 309.1K | ||||||||
| Total assets | 16.5M | 13.5M | 10.8M | 7.89M | 8.49M | 17.4M | 14.0M | 13.3M | 19.1M | 19.3M |
| Accounts payable | 316.2K | 440.0K | 948.7K | 1.38M | 1.00M | 760.8K | 1.20M | 1.01M | 1.24M | 939.8K |
| Current liabilities | 473.4K | 696.8K | 1.18M | 1.76M | 1.38M | 963.7K | 1.40M | 4.70M | 5.08M | 5.94M |
| Long-term debt | 0 | |||||||||
| Total debt | 128.1K | 169.0K | 15.9K | 103.7K | 66.4K | 24.8K | 76.9K | 2.75M | 120.0K | 132.5K |
| Total liabilities | 565.6K | 831.2K | 1.18M | 1.76M | 1.38M | 963.7K | 1.40M | 4.70M | 5.08M | 5.94M |
| Shareholders' equity | 16.0M | 12.7M | 9.88M | 6.30M | 7.11M | 16.4M | 12.6M | 8.60M | 14.0M | 13.3M |
| Shares outstanding | 9.17M | 494.8M | 334.3M | 178.1M | 102.5M | 73.6M | 882.4M | 226.0M | 203.9M | 124.3M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -1.51M | -189.7K | -1.48M | -932.1K | -12.3M | -1.70M | -3.59M | -6.85M | -12.3M | -5.42M |
| Capital spending | -1.51M | -2.09M | -2.85M | -2.26M | -3.11M | -1.83M | -1.54M | -1.14M | 0 | 0 |
| Free cash flow | -2.67M | -189.7K | -3.70M | -3.19M | -15.4M | -3.53M | -5.13M | -7.99M | -12.3M | -5.42M |
| Cash from investing | -1.17M | -2.09M | -2.85M | -2.26M | -3.11M | -1.83M | -1.50M | -1.06M | -399.6K | 34.2K |
| Cash from financing | 3.87M | 2.68M | 4.32M | 2.47M | 3.33M | 4.92M | 4.55M | 3.12M | 13.8M | 9.36M |
| Dividends paid | 0 | |||||||||
| Share buybacks | 2.73M | 4.70M | 2.51M | 3.38M | 4.97M | -140.9K | -1.05M | -1.20M | ||
| Change in cash | 1.20M | 398.7K | 634.0K | -818.5K | -1.28M | 1.50M | -520.6K | -4.79M | 1.11M | 3.97M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| TrivarX Appoints Emeritus Research for Phase 1 Study | Nov 10, 2026 | Operations update | ASX |
| September 2026 Quarterly Activities Report and Appendix 4C | Oct 29, 2026 | Quarterly report | ASX |
| September 2026 Quarterly Activities Report and Appendix 4C | Oct 29, 2026 | Quarterly report | ASX |
| Letter to Shareholders & Notice of AGM & Proxy Form | Oct 26, 2026 | Meeting notice | ASX |
| Syntro Health Appointed to Support Stabl-Im Clinical Program | Oct 21, 2026 | Operations update | ASX |
| Syntro Health Appointed to Support Stabl-Im Clinical Program | Oct 21, 2026 | Operations update | ASX |
| Change of Director's Interest Notice - David Trimboli | Oct 14, 2026 | Ownership change notice | ASX |
| Change of Director's Interest Notice - Chris Ntoumenopoulos | Oct 14, 2026 | Ownership change notice | ASX |
| Notification of cessation of securities - TRI | Oct 14, 2026 | Financing | ASX |
| Appendix 4G | Sep 29, 2026 | Other filings | ASX |
All 193 filings
Cap table
Built by 6ix from TrivarX Limited’s releases
- Common shares
- 1,153,693,464
- Fully diluted
- 1,153,693,464
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,153,693,464 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,153,693,464 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Chris Ntoumenopoulos | Non-executive Director · Since at least Nov 12, 2026 |
| Danielle Meyrick | Chief Executive Officer · Since at least Nov 11, 2026 |
| David Trimboli | Non-executive Chairman · Since at least Nov 12, 2026 |
| Kai Sun | Chief Operating Officer · Since at least Nov 11, 2026 |
| Tony Keating | Executive Director · Since at least Nov 12, 2026 |
Log in to ask 6ix AI your own questions about TrivarX Limited.